Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger population of patients with a genetic heart condition.
The FDA cleared the drug after the close on Thursday, allowing Alnylam to compete against Pfizer and BridgeBio to treat patients with the disease. Amvuttra sales are expected to top $1 billion next year, and reach $5.8 billion in 2030, according to analysts polled by FactSet.
Alnylam has long been a favorite among biotech investors, but the company hasn't yet shown it can transition from being a R&D innovator to a sustainable business. "We really are within touching distance of achieving sustainable profitability," said Chief Executive Yvonne Greenstreet in an interview. "Particularly in the current ecosystem, we feel that we're in rarefied air."
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
March 21, 2025 13:21 ET (17:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.